查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082040

肉毒桿菌毒素市場：按類型、劑型、給藥途徑、分銷管道、應用和最終用戶分類－2026-2032年全球市場預測

Botulinum Toxins Market by Type, Form, Mode of Administration, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肉毒桿菌毒素市場規模將達到 275.7 億美元，年複合成長率為 8.98%。

主要市場統計數據
基準年 2025 151億美元
預計年份：2026年 164.2億美元
預測年份 2032 275.7億美元
複合年成長率 (%) 8.98%

肉毒桿菌毒素是一種成熟的生物神經調節劑，廣泛應用於美容醫學、神經病學、皮膚病學、眼部科學、泌尿系統、消化病學和復健醫學等領域。市售產品主要來自A型和B型肉毒桿菌神經毒素，在主要市場均作為處方箋生物製藥進行監管。

市場需求主要受兩大持續且有數據支撐的趨勢驅動：一是國際美容整形外科學會（ISAPS）和美國美容整形外科學會（ASPS）等專業協會報告的微創美容手術高頻率；二是微創美容手術在治療慢性偏頭痛、頸肌肌張力不全症、成人及兒童痙攣、眼瞼痙攣、斜視、多汗、膀胱過動症產品差異化越來越注重起效時間、作用持續時間、純度、劑量一致性、已核准的適應症、從業人員訓練、低溫運輸可靠性和臨床證據強度。

肉毒桿菌毒素市場的變革性變化

肉毒桿菌毒素市場格局正從以化妝品應用為主導的高度集中領域，向多元化的處方生技藥品領域轉變，該領域涵蓋多種原研藥、生物相似藥和區域性批准產品。包括長效調變器劑在內的新製劑的法規核准，加劇了市場競爭，並提高了療效、安全性監測、藥物安全監管以及醫生教育在實際臨床實踐中的重要性。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過需求預測、庫存最佳化、低溫運輸監控、不利事件預警、患者細分、醫學教育以及銷售負責人的定向管理等方式，逐步影響肉毒桿菌毒素的商業化和臨床運營，從而確保合規性。電腦視覺工具可以輔助臉部評估、不對稱性記錄和治療方案製定，而電子健康記錄分析則有助於識別符合已批准適應症（例如慢性偏頭痛、痙攣和膀胱過動症）的患者。

對主要肉毒桿菌市場的關鍵區域洞察

北美仍然是肉毒桿菌毒素市場的主要地區，這得益於其大量的微創美容手術、廣泛的治療應用、針對特定醫療適應症的完善的保險報銷機制、專家的積極參與以及在神經科、皮膚科、泌尿系統和眼科領域完善的醫療網路。歐洲的優勢在於其成熟的法律規範體系、在皮膚科和神經科領域的高應用率以及跨境美容服務需求，同時，歐洲的藥品安全監測體系進一步提高了對品質、可追溯性和安全性報告的期望。

小組對肉毒桿菌策略的關鍵見解

七國集團（G7）憑藉其高額的醫療費用支出、高度專業化的醫療服務、完善的監管體係以及對已獲批准的醫療和美容適應症的早期應用，支撐著肉毒桿菌毒素的大部分使用。歐盟擁有統一的藥品監管體系、系統的藥品安全監測機制以及龐大的訓練有素的醫生隊伍，其成功的關鍵因素包括監管合規、產品可追溯性、從業人員教育以及多語種的醫療溝通。

肉毒桿菌毒素關鍵國家概況

美國憑藉其廣泛的FDA批准適應症、專業協會報告的大量神經調控手術案例，以及美容、神經、泌尿系統、眼科和皮膚科等領域專家的積極參與，引領市場。加拿大採用類似的實證臨床標準，但能否獲得治療取決於各州的保險報銷制度和個人在美容醫療方面的支出。墨西哥則受惠於手術的成本效益、醫療旅遊以及都市區完善的私人診所體系。巴西憑藉其蓬勃發展的美容行業、專業的培訓網路以及消費者對注射療法的持續接受度，仍然是拉丁美洲最重要的市場之一。

為行業領導者提供的實用建議

行業領導者應優先考慮產生臨床證據、監測真實臨床環境中的安全性以及提供差異化的醫學教育。清楚傳達已批准的適應症、禁忌症、起效時間、作用持續時間、劑量單位、稀釋、配製、儲存、注射技術以及不利事件處理方法，對於建立臨床醫生的信心和降低誤用風險至關重要。

調查方法

本執行摘要基於二手研究，參考了監管機構、臨床指南、產品標籤、同行評審文獻、專業學會外科報告、藥物警戒資料、保險報銷參考資料以及公共衛生相關資訊來源。市場分析考慮了已批准的適應症、安全警告、產品特性、治療環境、醫療基礎設施、保險報銷機制以及在美容和治療醫學領域的應用趨勢。

結論

肉毒桿菌毒素已發展成為臨床意義重大且商業性前景廣闊的處方生技藥品製劑。其廣泛應用得益於微創美容醫學的需求、不斷擴大的治療應用、醫生對其的熟悉程度、監管力度的加強以及在配方、純度、療效和作用持續時間方面的持續創新。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肉毒桿菌市場：依類型

  • A型肉毒桿菌毒素
  • B型肉毒桿菌

第8章 肉毒桿菌毒素市場：依劑型分類

  • 即用型液體
  • 凍乾粉

第9章 肉毒桿菌市場：依劑量方法分類

  • 皮內給藥
  • 肌肉內注射

第10章：肉毒桿菌市場：依分銷管道分類

  • 線下零售
  • 線上零售

第11章 肉毒桿菌市場：依應用領域分類

  • 美容應用
    • 臉部美
    • 多汗症
    • 非手術拉皮
  • 醫療用途
    • 消化系統疾病
    • 肌肉痙攣和麻痺
    • 疼痛管理

第12章 肉毒桿菌市場：依最終用戶分類

  • 皮膚科診所
  • 醫院和診所
  • 醫療水療中心
  • 研究和學術機構

第13章 肉毒桿菌毒素市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 肉毒桿菌市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肉毒桿菌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Ajinomoto Bio-Pharma Services
  • ATGC Co.,Ltd.
  • Bioplus Co., Ltd.
  • BMI KOREA CO., LTD.
  • BNC KOREA, INC.
  • Chong Kun Dang Pharmaceutical Corp.
  • Croma-Pharma GmbH
  • Daewoong Pharmaceuticals Co.Ltd.
  • Eirion Therapeutics, Inc.
  • Evolus, Inc.
  • Galderma SA
  • Genetox Co., Ltd.
  • Gufic Biosciences Ltd.
  • HUGEL, Inc.
  • Hugh Source International Ltd.
  • Huons Global Co., Ltd.
  • INIBIO Co., Ltd.
  • Ipsen Pharma
  • JETEMA, Co., Ltd.
  • Medytox Co., Ltd.
  • Merz Pharma GmbH & Co.KGaA
  • Object Pharma, Inc.
  • PharmaResearch Co. Ltd
  • Revance Therapeutics, Inc.
  • Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Taj Life Sciences Pvt. Ltd.
Product Code: MRR-4330CC794BD1

The Botulinum Toxins Market is projected to grow by USD 27.57 billion at a CAGR of 8.98% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.10 billion
Estimated Year [2026] USD 16.42 billion
Forecast Year [2032] USD 27.57 billion
CAGR (%) 8.98%

Botulinum toxins are established biologic neuromodulators used across medical aesthetics, neurology, dermatology, ophthalmology, urology, gastroenterology, and rehabilitation medicine. Commercially available products are derived from botulinum neurotoxin serotypes, primarily type A and type B, and are regulated as prescription biologics in major markets.

Demand is supported by two durable, data-backed trends: the high frequency of minimally invasive aesthetic procedures reported by professional societies such as ISAPS and ASPS, and expanding therapeutic use in conditions including chronic migraine, cervical dystonia, adult and pediatric spasticity, blepharospasm, strabismus, hyperhidrosis, sialorrhea, and overactive bladder. Product differentiation increasingly centers on onset, duration, purity profile, dosing consistency, approved indications, injector training, cold-chain reliability, and the strength of clinical evidence.

Transformative Shifts in the Botulinum Toxins Landscape

The botulinum toxins landscape is shifting from a highly concentrated, aesthetics-led category toward a diversified prescription biologics segment with multiple originator, biosimilar-like, and regionally approved products. Regulatory approvals for newer formulations, including longer-duration neuromodulators, have intensified competition and increased the importance of real-world effectiveness, safety monitoring, pharmacovigilance, and physician education.

A second transformation is the convergence of aesthetics and therapeutics. Clinics are adopting integrated treatment plans that combine neuromodulators with dermal fillers, energy-based devices, skincare regimens, migraine care pathways, muscle tone management, and rehabilitation protocols. At the same time, regulators, payers, and professional bodies continue to scrutinize appropriate use, product authentication, adverse-event reporting, counterfeit prevention, and evidence-based injection practice.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence botulinum toxin commercialization and clinical operations through demand planning, inventory optimization, cold-chain monitoring, adverse-event signal detection, patient segmentation, medical education, and compliant field-force targeting. Computer vision tools can support facial assessment, asymmetry documentation, and treatment planning, while electronic health record analytics can help identify eligible therapeutic patients for approved indications such as chronic migraine, spasticity, and overactive bladder.

The cumulative impact is operational and decision-support oriented rather than autonomous clinical substitution. AI can improve consistency, documentation, patient follow-up, training quality, and supply-chain visibility, but injection decisions remain dependent on licensed clinician judgment, anatomical expertise, informed consent, aseptic technique, and compliance with FDA, EMA, MHRA, PMDA, NMPA, TGA, and local regulatory requirements.

Key Regional Insights Across Major Botulinum Toxins Markets

North America remains a leading botulinum toxins region due to high minimally invasive aesthetic procedure volumes, broad therapeutic use, established reimbursement pathways for selected medical indications, strong specialist participation, and advanced neurology, dermatology, urology, and ophthalmology networks. Europe benefits from mature regulatory oversight, strong dermatology and neurology adoption, and cross-border demand for aesthetic services, while European pharmacovigilance systems reinforce expectations for quality, traceability, and safety reporting.

Asia-Pacific is expanding on the back of rising disposable income, medical tourism, social media-driven aesthetic awareness, and increasing acceptance of minimally invasive treatments across China, Japan, South Korea, India, Australia, and ASEAN markets. Latin America shows resilient aesthetic demand supported by Brazil and Mexico, where private clinics and strong beauty procedure cultures are important adoption drivers. The Middle East is supported by premium private clinics, high consumer spending in GCC countries, and growing medical tourism hubs, while Africa remains earlier-stage, with adoption concentrated in urban private healthcare settings, specialist dermatology centers, and higher-income patient groups.

Key Group Insights for Botulinum Toxins Strategy

The G7 anchors a significant portion of botulinum toxin adoption through high healthcare spending, advanced specialist practice, established regulatory systems, and early use of approved medical and cosmetic indications. The European Union adds harmonized medicine oversight, structured pharmacovigilance, and a large base of trained physicians, making regulatory compliance, product traceability, injector education, and multilingual medical communication critical success factors.

BRICS markets are increasingly important because China, India, and Brazil combine large populations with expanding private healthcare access, rising medical aesthetics interest, and growing specialist capacity, while Russia remains shaped by import access, local authorization requirements, and healthcare system dynamics. ASEAN offers opportunity through urbanization, medical tourism, and expanding private aesthetic clinics, while the GCC is characterized by premium positioning, high consumer willingness to pay, and strong demand for physician-led cosmetic procedures. NATO markets overlap substantially with high-income medical systems, supporting institutional procurement, stringent quality standards, and disciplined pharmacovigilance expectations.

Key Country Insights for Botulinum Toxins

The United States leads through broad FDA-approved indications, high neuromodulator procedure volumes reported by professional societies, and strong specialist participation across aesthetics, neurology, urology, ophthalmology, and dermatology. Canada follows similar evidence-based clinical standards, with access shaped by provincial reimbursement and private aesthetic spending, while Mexico benefits from procedure affordability, medical tourism, and a strong urban private clinic base. Brazil remains one of the most important Latin American markets due to high aesthetic procedure activity, specialist training networks, and sustained consumer acceptance of injectable treatments.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from mature specialist networks, established aesthetic medicine ecosystems, and regulated medical product oversight, while Russia is influenced by import access, local regulatory dynamics, and private healthcare demand. China, India, Japan, South Korea, and Australia are central to Asia-Pacific adoption: China offers scale and expanding aesthetic demand; India is supported by affordability-driven private healthcare expansion; Japan emphasizes regulated medical practice and quality expectations; South Korea is known for advanced aesthetic adoption, practitioner expertise, and medical tourism; and Australia is shaped by strong clinical governance, prescription medicine controls, and high patient safety expectations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence generation, real-world safety monitoring, and differentiated medical education. Clear communication on approved indications, contraindications, onset, duration, dosing units, dilution, reconstitution, storage, injection technique, and adverse-event management is essential for building clinician trust and reducing misuse risk.

Commercial strategies should combine premium brand positioning with responsible access models for therapeutic indications. Leaders should invest in authenticated distribution, cold-chain integrity, counterfeit prevention, injector certification, patient education, AI-enabled demand planning, compliant digital engagement, and region-specific regulatory engagement to protect safety, supply reliability, margin discipline, and long-term brand equity.

Research Methodology

This executive summary is grounded in secondary research from regulatory agencies, clinical guidelines, product labeling, peer-reviewed literature, professional society procedure reports, pharmacovigilance resources, reimbursement references, and public health sources. Market interpretation considers approved indications, safety warnings, product characteristics, treatment settings, healthcare infrastructure, reimbursement structures, and adoption patterns across aesthetics and therapeutics.

Insights are validated through cross-comparison of regional regulatory maturity, specialist availability, procedure demand, medical aesthetics adoption, therapeutic care pathways, distribution requirements, and competitive activity. The methodology emphasizes verified, publicly supportable evidence and avoids unsupported claims, market estimation, market sizing, market share analysis, and market forecasting.

Conclusion

Botulinum toxins have evolved into a clinically important and commercially resilient prescription biologics category. Adoption is supported by demand for minimally invasive aesthetics, broadening therapeutic applications, physician familiarity, regulatory oversight, and ongoing innovation in formulation, purity profile, onset, and duration.

The next phase of competition will reward organizations that combine strong safety evidence, trusted clinical training, compliant promotion, resilient cold-chain distribution, counterfeit safeguards, and digital intelligence. Stakeholders that balance patient outcomes with responsible commercialization will be best positioned across the global botulinum toxins landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Botulinum Toxins Market, by Type

  • 7.1. Botulinum Toxin Type A
  • 7.2. Botulinum Toxin Type B

8. Botulinum Toxins Market, by Form

  • 8.1. Ready-To-Use Liquid
  • 8.2. Lyophilized Powder

9. Botulinum Toxins Market, by Mode of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular

10. Botulinum Toxins Market, by Distribution Channel

  • 10.1. Offline Retail
  • 10.2. Online Retail

11. Botulinum Toxins Market, by Application

  • 11.1. Aesthetic Applications
    • 11.1.1. Facial Aesthetics
    • 11.1.2. Hyperhidrosis
    • 11.1.3. Non-Surgical Facelifts
  • 11.2. Medical Applications
    • 11.2.1. Gastrointestinal Disorders
    • 11.2.2. Muscle Spasms & Paralysis
    • 11.2.3. Pain Management

12. Botulinum Toxins Market, by End User

  • 12.1. Dermatology Clinics
  • 12.2. Hospitals & Clinics
  • 12.3. Medical Spas
  • 12.4. Research & Academic Institutes

13. Botulinum Toxins Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Botulinum Toxins Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Botulinum Toxins Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Ajinomoto Bio-Pharma Services
  • 17.3. ATGC Co.,Ltd.
  • 17.4. Bioplus Co., Ltd.
  • 17.5. BMI KOREA CO., LTD.
  • 17.6. BNC KOREA, INC.
  • 17.7. Chong Kun Dang Pharmaceutical Corp.
  • 17.8. Croma-Pharma GmbH
  • 17.9. Daewoong Pharmaceuticals Co.Ltd.
  • 17.10. Eirion Therapeutics, Inc.
  • 17.11. Evolus, Inc.
  • 17.12. Galderma SA
  • 17.13. Genetox Co., Ltd.
  • 17.14. Gufic Biosciences Ltd.
  • 17.15. HUGEL, Inc.
  • 17.16. Hugh Source International Ltd.
  • 17.17. Huons Global Co., Ltd.
  • 17.18. INIBIO Co., Ltd.
  • 17.19. Ipsen Pharma
  • 17.20. JETEMA, Co., Ltd.
  • 17.21. Medytox Co., Ltd.
  • 17.22. Merz Pharma GmbH & Co.KGaA
  • 17.23. Object Pharma, Inc.
  • 17.24. PharmaResearch Co. Ltd
  • 17.25. Revance Therapeutics, Inc.
  • 17.26. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • 17.27. Supernus Pharmaceuticals, Inc.
  • 17.28. Taj Life Sciences Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOTULINUM TOXINS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BOTULINUM TOXINS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BOTULINUM TOXINS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BOTULINUM TOXINS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOTULINUM TOXINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BOTULINUM TOXINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BOTULINUM TOXIN TYPE A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BOTULINUM TOXIN TYPE A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOTULINUM TOXIN TYPE A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BOTULINUM TOXIN TYPE B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOTULINUM TOXIN TYPE B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BOTULINUM TOXIN TYPE B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL READY-TO-USE LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL READY-TO-USE LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL READY-TO-USE LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OFFLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OFFLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OFFLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONLINE RETAIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONLINE RETAIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONLINE RETAIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AESTHETIC APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AESTHETIC APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AESTHETIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FACIAL AESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FACIAL AESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FACIAL AESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYPERHIDROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYPERHIDROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYPERHIDROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-SURGICAL FACELIFTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-SURGICAL FACELIFTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-SURGICAL FACELIFTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GASTROINTESTINAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MUSCLE SPASMS & PARALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MUSCLE SPASMS & PARALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MUSCLE SPASMS & PARALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MEDICAL SPAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MEDICAL SPAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MEDICAL SPAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 136. GCC BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GCC BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 163. G7 BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. G7 BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BOTULINUM TOXINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 214. BRAZIL BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 250. RUSSIA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. ITALY BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. SPAIN BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. SPAIN BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. INDIA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. INDIA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. INDIA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. JAPAN BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. JAPAN BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 295. JAPAN BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY AESTHETIC APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY MEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA BOTULINUM TOXINS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)